Trialstirzepatideeli lillypediatric obesityphase 3

Lilly registers Phase 3 tirzepatide trial in children aged 6 to 12

ADVANCE-SURMOUNT-KIDS will run about 104 weeks, with an optional 156-week extension for participants who complete the primary study.

By Priya Raman · Science Reporter

Sep 25 08:00 ETSource: ClinicalTrials.gov

The wire

01Eli Lilly posted NCT07816875-listed Phase 3 trial ADVANCE-SURMOUNT-KIDS, testing once-weekly tirzepatide versus placebo alongside lifestyle intervention in participants 6 to under 12 years with obesity, starting September 2026.
02Extending incretin therapy into pre-adolescent children would widen prescribing questions for pediatric and primary care clinicians already handling adolescent demand.
03The trial is not yet recruiting and runs under master protocol J4M-MC-PWMP; efficacy, safety and pharmacokinetic readouts are years away.

From the source

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875 · PHASE3 · NOT YET RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07817875